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Abstract
Background: There is increasing interest in non-pharmacological control of cholesterol and triglyceride levels in
the plasma and diet-drug association represent an important area of studies. The objective of this study was to
observe the hypocholesterolemic effect of soybean b-conglycinin (7S protein) alone and combined with
fenofibrate and rosuvastatin, two hypolipidemic drugs.
Methods: The protein and drugs were administered orally once a day to rats and the effects were evaluated after
28 days. Wistar rats were divided into six groups (n = 9): hypercholesterolemic diet (HC), HC+7S protein (300 mg.kg-1
day-1) (HC-7S), HC+fenofibrate (30 mg.kg-1 day-1)(HC-FF), HC+rosuvastatin (10 mg.kg-1 day-1)(HC-RO),
HC+7S+fenofibrate (HC-7S-FF) and HC+7S+rosuvastatin (HC-7S-RO).
Results: Animals in HC-7S, HC-FF and HC-RO exhibited reductions of 22.9, 35.8 and 18.8% in total plasma
cholesterol, respectively. In HC-7S-FF, animals did not show significant alteration of the level in HC+FF while the
group HC-7S-RO showed a negative effect in comparison with groups taking only protein (HC-7S) or drug (HC-RO).
The administration of the protein, fenofibrate and rosuvastatin alone caused increases in the plasma HDL-C of the
animals, while the protein-drug combinations led to an increase compared to HC-FF and HC-RO. The plasma
concentration of triacylgycerides was significantly reduced in the groups without association, while HC-7S-FF
showed no alteration and HC-7S-RO a little reduction.
Conclusion: The results of our study indicate that conglycinin has effects comparable to fenofibrate and rosuvastatin on
the control of plasma cholesterol, HDL-C and triacylglycerides, when given to hypercholesterolemic rats, and suggests
that the association of this protein with rosuvastatin alters the action of drug in the homeostasis of cholesterol.
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Background
Some proteins and peptides have been under study on
account of their important biological function in relation
to lipid metabolism [1-3]. Research has demonstrated the
importance of leguminous seeds, as a component of the
diet including their beneficial effect on the control of
cholesterol and triacylglycerols in the blood, with an
emphasis on their proteins and in particular soybean pro-
teins [4,5]. In vitro and in vivo studies have shown that
ingestion of protein isolate and/or protein fractions of
soybean, as the sole source of protein or even a daily
dose, improves the control of plasma cholesterol and tri-
glycerides [6-15]. A recent analysis of various studies
about the effects of soybean in the diet on the circulation
levels of cholesterol indicates a variable reduction in
LDL-C (from 7.9 to 10.3%) attributed to intrinsic and
extrinsic effects of the soy protein foods [16]. Although
these studies in various models have achieved progress in
this area, the mechanism of the reduction of cholesterol
and triacylglycerides in the serum by soybean proteins
are still not clear. Nevertheless, the observed effects of
soybean proteins was the basis on which the US Food
and Drug Administration (FDA) made a recommenda-
tion that 25 g of soybean protein be ingested to decrease
total cholesterol and the LDL-cholesterol fraction [17].
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any medium, provided the original work is properly cited.A lot of studies have stressed the diet as an important
form of intervention, alone or together with drugs, in the
context of hyperlipidemia or hypercholesterolemia in
their various forms [4,18]. The treatment of hyperlipide-
mia and hypercholesterolemia with a diet-drug combina-
tion is well recognized and has been growing in
importance in recent times [19]; nevertheless, these com-
bination therapies have received less attention than
multi-drug therapy [18,20]. Fibrates and their derivatives
are hypolipidemic agents widely used in the treatment of
combined hyperlipidemias, however they are particularly
effective at reducing serum triacylglycerols and improv-
ing serum high-density lipoprotein (HDL) [21,22].
Statins are used in the treatment of hypercholesterole-
mia, and the action of this class of drugs depends on their
generation and dose. These drugs have an inhibitory
action on cholesterol synthesis via the mevalonate pathway
[18,23]. The positive effects of b-conglycinin soybean pro-
tein, taken as a daily dose or a sole protein source by rats
fed a hypercholesterolemic diet, on TC and TG levels have
been described in previous studies [13-15]. However, the
combination of this protein with other antihyperlipidemic
drugs has not been much reported. Drug-diet approaches
may help in controlling the prescription of drugs, but stu-
dies are needed to be performed to explore novel combi-
nations and assess the potential safety and effectiveness of
the association, comparing its efficacy with treatment by
each component alone. To observe of the effect of soybean
b-conglycinin alone and in combination with two drugs
effective in the treatment of dyslipidemia, fenofibrate and
rosuvastatin, the present study was conducted to deter-
mine whether the association of b-conglycinin soy protein
and either drug could result in an alteration of the action
of the protein or the drug alone.
Methods
Isolation and characterization of b-conglycinin (7S)
Soybean flour from the local market (60 mesh) was
defatted with hexane (1:8 w/v flour to solvent ratio) by
rocking at room temperature for 12 h, followed by reex-
traction in the same solvent (1:6 w/v), dried in air at room
temperature and used for protein extraction. Soybean b-
conglycinin was isolated by the method of Nagano et al.
[24] with some modifications. Defatted soybean flour was
extracted by shaking with water (1:15 w/v flour to water
ratio) adjusted to pH 7.5. The soluble extract was centri-
fuged at 2000 × g for 30 min. The supernatant was treated
with anhydrous sodium bisulphite (0.98 g/L) and the pH
adjusted to 6.4. The solution was stirred and stored on ice
overnight, followed by centrifugation at 6500 × g for
20 min. The insoluble fraction, containing 11S globulin,
was washed, centrifuged again under the same conditions,
suspended in distilled water, dialyzed overnight against
distilled water in appropriate dialysis sacs (pore size of
about 10 kDa) and lyophilized. The soluble fraction was
treated with 0.25 mol/L NaCl and adjusted to pH 5.0 and,
after 1 h, centrifuged at 9000 × g for 30 min. The precipi-
tate (7S or b-conglycinin) was solubilized in 0.25 mol/L
sodium phosphate buffer (pH 7.0) and stored at -14°C. All
steps were realized at 4°C. All chemicals were of analytical
purity. Protein was determined by the method of Lowry
et al. [25], using bovine serum albumin (BSA) as a stan-
dard. Electrophoresis of 7S-globulin was performed on
10 g/100 g polyacrylamide gels containing 0.1% sodium
dodecyl sulfate (SDS), as described by Laemmli [26], in a
Mini Protean II cell (Bio-Rad, Hercules, CA, USA)(SDS-
PAGE). The gels were stained in Coomassie Brilliant Blue
(R-250) and destained by diffusion in methanol-acetic
acid-water (1:1:8, v/v/v). Marker proteins of known mole-
cular weight (MW) were rabbit muscle phosphorylase b,
bovine serum albumin, hen egg white albumin, bovine car-
bonic anhydrase, soybean trypsin inhibitor and hen egg
white lysozyme. Gel images were digitalized and analyzed
by densitometry with an alpha Imager 6.0 scanner (Alpha
Innotech
®, San Leandro, CA, USA), to quantify the bands
and level of purity (data not shown). The content and
homogeneity of the isolated b-conglycinin and glycinin,
determined by SDS-PAGE and densitometric gel analysis,
showed that these were the main fractions. The gels
showed the characteristic bands for subunits a, a’ and b
of conglycinin (7S). The procedure used to isolate 7S did
not cause changes in the subunits; this step was essential
to ensure a pure protein, suitable for the in vivo studies
[15].
Animals, diets and experimental design
This study was performed with the approval of the Com-
mittee on Animal Research of the University (UNESP)
and these experiments were approved by the Research
Ethics Committee of the School of Pharmaceutical
Sciences, São Paulo State University (UNESP) at Arara-
quara (res. 19/2007). All procedures were performed in
accordance with the principles in the Guide for the Care
and Use of Laboratory Animals (National Research
Council, 1985). Fifty-four male weanling Wistar rats,
weighing 148 ± 12.3 g were obtained from the Central
Laboratory for animals of UNESP at Botucatu. The ani-
mals were acclimatized for a week and fed standard
laboratory rat chow (Purina
®). After this period, they
were randomly divided into 6 hypercholesterolemic
groups (HC) (n=9 ): (1) control HC; (2) 7S globulin,
300 mg.kg
-1 day
-1 (HC+7S); (3) fenofibrate group
(HC+FF, 30 mg.kg
-1 day
-1); (4) rosusvatatin group (HC
+RO 10 mg.kg
-1 day
-1); (5) b-conglycinin/fenofibrate
group (HC+7S+FF, 300 and 30 mg.kg
-1 day
-1)a n d( 6 )b-
conglycinin/rosuvastatin group (HC+7S+RO, 300 and
10 mg.kg
-1 day
-1). All HC groups were fed an AIN-93
diet, following the recommendation of American
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adding 10 g.kg
-1 cholesterol and 5 g.kg
-1 gc h o l i ca c i d
[13,28], as described in Table 1. Animals were individu-
ally housed in stainless steel cages, with free access to
food and water. The room temperature was maintained
at a constant 23 ± 2°C and relative humidity at 60 ± 5%,
with a 12-12 h light:dark cycle, lights on at 6:00 a.m. The
proteins (7S globulins) and drugs were administered daily
by gavage at 9:00 and 14:00 hours, in proportion to the
body weight of each animal, while vehicle alone was
administered to HC groups. Body weight, food intake,
fecal excretion and feeding efficiency were measured
every other day for comparative analysis between groups
during the 28 days of the experiment. The feeding effi-
ciency coefficient was calculated as the ratio of weight
gain/daily intake × 100.
Blood collection, organ weight and tissue collection
On the last day, the animals were deprived of food for
12 h and euthanized by guillotine. Blood was then col-
lected in tubes containing gel separator SST II (Vacutai-
ner BD D
®, Franklin Lakes, NJ, USA) and centrifuged at
1900 × g for 15 min. The serum was separated, stored
at -24°C and used for biochemical analysis. Retroperito-
neal fat, liver and heart were removed, washed immedi-
ately in cold saline, dried and weighed, frozen and
stored at -40°C for a period of less than a month for
subsequent comparative analysis.
Biochemical analysis in plasma and liver
Plasma total cholesterol (TC) of all groups was mea-
sured by the liquid cholesterol CHOD-PAP method
described by Stockbridge et al. [29]. Serum high density
lipoprotein (HDL-C) was measured by the HDL choles-
terol precipitant method, as described by Assmann [30].
Triglycerides (TG) were measured by the liquid trigly-
ceride GPO-PAP method, as described by Annoni et al.
[31]. All analyses were carried out by enzymatic colori-
metric methods, using commercially available reagent
kits (Laborlab
®Co., Ribeirão Preto, Brazil). The non-
HDL-cholesterol fraction (non-HDL-C or LDL-C +
VLDL-C) was calculated as the difference between the
TC and HDL-C. The atherogenic index (AI) (TC-HDL-
C/HDL-C) was calculated, as proposed by Liu et al. [32],
and compared among groups. Hepatosomatic index
(HIS) was calculated as follows: liver weight/body weight
× 100. Liver lipids were extracted by the method of
Haug et al. [33]. The liver TC and TG concentrations
were measured as described earlier for plasma analysis.
Statistical Analysis
Data were analyzed by one-way analysis of variance
(ANOVA) and Bonferroni t-test multiple comparisons
versus the control group and multiple range tests,
employing SigmaStat
® 3.5 software (Dundas software,
Germany, 1999). All values are presented as mean ±
standard error for nine values per group. A difference
was considered statistically significant when P < 0.05.
Results
Isolation of the soybean b-conglycinin
SDS-PAGE electrophoresis, conducted on the 7S globu-
lin after separation from other protein components in
soybean flour, showed the characteristic bands of
Table 1 Composition (g/kg diet) of the hypercholesterolemic diet and treatments by gavage*
Ingredient Diets
HC HC+7S HC+FF HC+RO HC+7S+FF HC+7S+RO
Casein
1 150 150 150 150 150 150
Starch 590.57 590.87 590.87 590.87 590.87 590.87
Sucrose 100 100 100 100 100 100
Soybean oil 40 40 40 40 40 40
Cellulose powder 50 50 50 50 50 50
Mineral mixture
2 35 35 35 35 35 35
Vitamin mixture
2 10 10 10 10 10 10
L-Cystine 1.8 1.8 1.8 1.8 1.8 1.8
Choline birtatrate 2.5 2.5 2.5 2.5 2.5 2.5
Cholesterol
3 111 1 1 1
Cholic acid
1 555 5 5 5
Treatment (mg/kg/day)
b-conglycinin - 300.0 - - 300 300
Fenofibrate - - 30 - 30 -
Rosuvastatin - - - 10 - 10
*HC = hypercholesterolemic diet (AIN-93 composition + 1% cholesterol and 0.5% cholic acid); HC+7S = HC diet + b-conglycinin 300 mg/Kg/day; HC+FF = HC diet
+ fenofibrate 30 mg/Kg/day; HC+RO = HC diet + rosuvastatin 10 mg/kg/day; HC+7S+FF = HC diet + b-conglycinin + fenofibrate 300 and 30 mg/kg/day and HC
+7S+RO = HC diet + b-conglycinin + rosuvastatin 300 and 10 mg/kg/day.
1Sigma-Aldrich, Co., USA,
2PragSoluções
®, Co., Brazil.
3Reagen, Co., USA.
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nits, and densitometric gel analysis showed that this was
the main fraction, containing 92.2% of the protein. The
isolation procedure did not cause any change in the sub-
units and was important to obtain purified protein suita-
ble for the in vivo studies [14,15]. Our previous results
and those decribed by Duranti et al. [13] have shown
that the addition of 1% cholesterol and 0.5% cholic acid
to the AIN-diet is sufficient to induce hypercholesterole-
mia and hypertriglyceridemia in rats. The mechanism of
these effects on the lipid metabolism of rats was
reported by Wang et al. [34], recently.
b-conglycinin protein and drugs were given by gavage in
single daily doses in the experimental design as described
in methods. Table 2 shows the effects of daily administra-
tion of b-conglycinin, fenofibrate and rosuvastatin alone
and in drug-protein combinations, on the food consump-
tion, weight gain, feeding efficiency ratio and fecal excre-
tion of rats fed the cholesterol-enriched diets. After 28
days, no statistical differences (p> 0.05) were found in
body weight gain between groups during the experimental
period, nor any significant (p > 0.05) alterations in the
feeding efficiency ratio or food intake between groups
(Table 2). However, the animal fecal excretion of the HC
group was higher by 18.1, 18.1, 42.9, 21.7 and 50.7% than
groups HC+7S, HC+FF, HC+RO, HC+7S+FF and HC+7S
+RO, respectively (p < 0.001), despite the lack of differ-
ences in food intake or feeding efficiency ratio between
groups. However, the rosuvastatin-treated animals did
show an intake 8.72% higher than HC animals (p < 0.001).
The fenofibrate and rosuvastatin groups showed increases
of 55.8 and 63.2% (p < 0.001), and 26.1 and 21.1% (p <
0.05), in the relative liver weight and in the hepatosomatic
index (HIS), respectively (Tab l e3 ) .T h es i m u l t a n e o u s l y
administration of protein and drugs reduced these effects
by 8.4 and 16.1% for fenofibrate (HC+7S+FF) and 24.8
and 16.7% for rosuvastatin (HC+7S+RO), relative to
groups HC+FF and HC+RO, respectively. Alterations in
heart weight and the ratio heart weight/body weight were
not observed.
Effects on plasma lipids
The levels of plasma lipids in group HC were significantly
different (p < 0.001) from those fed a standard diet [14];
these animals showed a 43.6% reduction in HDL-C levels
a n da ni n c r e a s ei nn o n - H D L - Ca n di nt h ea t h e r o g e n i c
index of 4 and 7 times, relative to a group on the standard
diet in the first part of this study [15]. Relative to HC
groups HC+7S, HC+ FF and HC+RO had their total
plasma cholesterol (TC) reduced by 22.9 (p < 0.01), 35.8
(p < 0.001) and 18.8% (p < 0.05), respectively (Table 4).
There was no significant alteration in the animals that
received the 7S protein plus fenofibrate (HC+7S+FF),
whereas the association of protein plus rosuvastatin (HC
+7S+RO) caused a negative effect, when the TC levels of
these groups were compared with those administered only
protein (HC+7S) or drug (HC+FF and HC+RO). For the
fraction non-HDL-C, a similar effect was observed with
reductions of 33.2, 53.1 and 28% (p < 0.001) for groups
HC+7S, HC+FF and HC+RO, respectively, while decreases
of 59.5 (p < 0.001) and 15.2% (p < 0.05) were registered for
groups HC+7S+FF and HC+7S+RO. In contrast to rosu-
vastatin, the protein-fenofibrate association led to an
increase of 11.2% (p < 0.05) (Table 4). The administration
of the protein, fenofibrate and rosuvastatin alone caused
increases in the plasma HDL-C of the animals by 55.6,
95.6 e 51.1% in relation to HC, respectively, (p < 0.001),
while the protein-drug associations led to increases of 6
a n d3 7 % ,c o m p a r e dt oH C + F Fa n dH C + R Og r o u p s ,
respectively (p > 0.05) (Table 4). The atherogenic index
(AI) showed decreases of 56.5, 75.8 and 49.4% in HC+7S,
HC+FF and HC+RO (p < 0.001) in relation to HC, respec-
tively, as a consequence of these effects. The combination
of the protein-FF and protein-RO led to increases in AI of
5.3 and 5.2%, respectively (p > 0.05).
Triacylglycerol (TG) plasma concentrations of the ani-
mals in groups HC+7S and HC+FF showed significant
reductions (p < 0.001) of 34.8 and 45.7%, whereas group
HC+RO had only a slight reduction of 7.6% (p > 0.05),
relative to HC. For protein-drug combinations, the b-
conglycinin/fenofibrate group (HC+7S+FF) did not show
Table 2 Body weight change, food intake, and feeding efficiency ratio (FER) of rats fed HC diets and treated with
separate and combined doses of b-conglycinin, fenofibrate and rosuvastatin
Dietary groups
1
HC HC+7S HC+FF HC+RO HC+7S+FF HC+7S+RO
Initial weight (g/rat) 196.55 ± 4.63 195.26 ± 3.64 193.26 ± 3.64 193.33 ± 2.27 193.18 ± 3.62 194.22 ± 3.14
Final weight (g/rat) 295.01 ± 5.43 300.64 ± 7.71 281.14 ± 4.25 306.11 ± 3.79 306.64 ± 7.71 284.33 ± 8.01
Weight gain (g/rat/day) 3.51 ± 0.32 3.76 ± 0.29 3.14 ± 0.29 4.02 ± 0.16 4.05 ± 0.17 3.22 ± 0.28
Food intake (g/rat/day) 16.74 ± 0.33 16.25 ± 0.22 16.25 ± 0.22 18.20 ± 0.17** 15.61 ± 0.30 17.68 ± 0.25
Fecal excretion (g/rat/day) 3.59 ± 0.12 2.94 ± 0.09* 2.94 ± 0.09* 2.05 ± 0.12** 2.83 ± 0.09* 1.77 ± 0.13**
Feeding efficiency (%) 21.01 ± 1.44 23.05 ± 1.93 23.21 ± 1.93 21.35 ± 0.85 20.90 ± 1.51 18.25 ± 1.34
1Values are means ± SEM for nine rats. *p < 0.05 and **p < 0.001 by the Bonferroni t-test for multiple comparisons versus control group (HC). HC =
hypercholesterolemic diet; HC+7S = HC diet + b-conglycinin 300 mg/kg/day; HC+FF = HC diet + fenofibrate 30 mg/kg/day; HC+RO = HC diet + rosuvastatin 10
mg/Kg/day; HC+7S+FF = HC diet + b-conglycinin + fenofibrate, 300 and 30 mg/kg/day respectively, and HC+7S+RO = HC diet + b-conglycinin + rosuvastatin, 300
and 10 mg/kg/day respectively.
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(HC+7S+RO) showed a reduction of 23.9% in the TG
levels (p < 0.05) relative to the respective drug-treated
groups (HC+FF and HC+RO) (Table 4).
Effects on hepatic lipids
Table 4 shows that groups HC+7S had reductions of 20.9
and 14.8% in the liver cholesterol and triacylglycerol con-
centrations, compared to HC, respectively (p <0 . 0 0 1 ) .
Groups HC+FF and HC+RO had 32.3 and 38.3% less cho-
lesterol than HC, respectively (Table 4); on the other
hand, group HC+RO had a 27.3% reduced liver TG con-
centration, while HC+FF did not show significant altera-
tion in this parameter (p < 0.001).
Discussion
T h ee f f e c t so ff i b r a t e sa n ds t a t i n sa sd r u g sf o rt h et r e a t -
ment of dyslipidemias are well described in the literature
and their mechanisms of action practically established
[21,23]. The action of these compounds is associated
with transcriptional control of triglycerides metabolism
by the activation of the transcription factor PPAR-a (per-
oxisome proliferator-activated receptor) and consequent
induction of the enzymes of b-oxidation of fatty acids in
mitochondria. Statins inhibit endogenous cholesterol
synthesis by inhibition of 3-hydroxy-3-methyl-glutamyl-
CoA reductase, the rate-limiting enzyme in cholesterol
synthesis. Depending on which generation of statin is
used the various doses lead to reductions of LDL-C (low-
density lipoprotein cholesterol) in a range between 20
and 60% [23]. Diet components, such as plant sterols/
stanols, soluble fibers, omega-3-fatty acids, niacin and
soybean components; have been combined with a variety
of drugs, in experiments in vitro and in vivo, to treat dys-
lipidemia [18].
In our experiment, the differences in body weight gain
between groups were not significant, although the weights
of the livers of rats consuming the mixture of drugs and
7S-FF were much higher than those of other groups. The
group that received rosuvastatin had a liver weight gain
lower than those given fenofibrate. The observed increase
in liver weight by administration of fenofibrate is reported
in the literature. Yamamoto et al. [22] found such an
increase on administering fenofibrate at 0.05% in diet of
rats, while, Mancini et al. [35] observed an increase of
30.2% in the liver weight of hyperlipidemic rats after daily
Table 4 Effect of diets on plasma lipid profiles and hepatic lipid contents in rats fed hypercholesterolemic diets and
treated with doses of b-conglycinin, fenofibrate, rosuvastatin and mixtures
Dietary groups
HC HC+7S HC+FF HC+RO HC+7S+FF HC+7S+RO
Plasma (mmol/L)
Total cholesterol 3.88 ± 0.22 2.99 ± 0.10* 2.49 ± 0.15** 3.15 ± 0.12* 2.33 ± 0.22** 4.00 ± 0.12
HDL-C 0.45 ± 0.02 0.70 ± 0.05* 0.88 ± 0.13* 0.68 ± 0.06 0.93 ± 0.10** 0.90 ± 0.15*
non-HDL-C 3.43 ± 0.12 2.29 ± 0.10** 1.61 ± 0.06** 2.47 ± 0.14** 1.39 ± 0.12** 2.91 ± 0.22*
Triacylglycerides 0.92 ± 0.05 0.60 ± 0.04** 0.50 ± 0.02** 0.85 ± 0.07 0.49 ± 0.03** 0.70 ± 0.05*
AI* 8.09 ± 0.07 3.52 ± 0.11** 1.96 ± 0.12** 4.09 ± 0.35** 1.53 ± 0.15** 3.67 ± 0.33**
Liver (μmol/g)
Total cholesterol 58.43 ± 0.85 46.22 ± 0.65** 39.58 ± 0.85** 36.04 ± 2.07** 37.86 ± 0.80** 47.13 ± 2.12**
Triacylglycerides 56.97 ± 2.15 48.52 ± 2.28* 60.06 ± 1.76 41.42 ± 2.46** 47.64 ± 2.38* 46.05 ± 2.59*
1Values are means ± SEM for nine rats. *p < 0.05 and **p < 0.001 by the Bonferroni t-test multiple comparisons versus control group (HC). HC =
hypercholesterolemic diet; HC+7S = HC diet + b-conglycinin 300 mg/kg/day; HC+FF = HC diet + fenofibrate 30 mg/kg/day; HC+RO = HC diet + rosuvastatin 10
mg/kg/day; HC+7S+FF = HC diet + b-conglycinin + fenofibrate, 300 and 30 mg/kg/day respectively, and HC+7S+RO = HC diet + b-conglycinin + rosuvastatin, 300
and 10 mg/kg/day respectively. * AI = atherogenic index ware calculated as proposed by Liu et al. (2006).
Table 3 Tissue weight of rats fed HC diets and treated with doses of b-conglycinin, fenofibrate, rosuvastatin and
mixtures
Dietary groups
1
HC HC+7S HC+FF HC+RO HC+7S+FF HC+7S+RO
Liver weight (g/rat) 13.54 ± 0.36 13.55 ± 0.87 21.10 ± 0.69** 17.07 ± 0.92* 19.32 ± 0.38** 12.83 ± 0.51
Heart (g/rat) 1.03 ± 0.04 0.94 ± 0.03 0.95 ± 0.03 1.26 ± 0.05 0.96 ± 0.02 0.89 ± 0.05
Hepatossomatic índex* (HI) 4.59 ± 0.14 4.41 ± 0.20 7.51 ± 0.27** 5.56 ± 0.27* 6.30 ± 0.12** 4.63 ± 0.16
Heart weight/body weight (g/100 g) 0.34 ± 0.01 0.30 ± 0.02 0.34 ± 0.01 0.41 ± 0.02* 0.33 ± 0.01 0.32 ± 0.01
1Values are means ± SEM for nine rats. *p < 0.05 and **p < 0.001 by the Bonferroni t-test multiple comparisons versus control group (HC). HC =
hypercholesterolemic diet; HC+7S = HC diet + b-conglycinin 300 mg/kg/day; HC+FF = HC diet + fenofibrate 30 mg/kg/day; HC+RO = HC diet + rosuvastatin 10
mg/kg/day; HC+7S+FF = HC diet + b-conglycinin + fenofibrate, 300 and 30 mg/kg/day respectively, and HC+7S+RO = HC diet + b-conglycinin + rosuvastatin, 300
and 10 mg/kg/day respectively. Hepatossomatic índex (HI) = liver weight/body weight × 100.
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-1 of fenofibrate for 120 days.
Ji et al. [36] observed an increase in the liver weight of the
animals fed on a hyperlipidemic diet and treated with ator-
vastatin at a dose of 30 mg.kg
-1 day
-1 for 8 weeks; the
authors also showed an increase in the hepatosomatic
index of these animals. These results are consistent with
published reports of liver hypertrophy after fenofibrate
administration, due to proliferation of peroxisomes and
mitochondria. In our study, the raised hepatosomatic
index of the animals that received fenofibrate thus resulted
from the high liver weight and the insignificant body
weight gains of the animals (Table 2 and 3). The protein-
drug combination caused reductions of 16 and 16.7% in
the hepatosomatic indices of the animals that ingested
fenofibrate and rosuvastatin, respectively, and in the latter
case practically annulled the effect of the drug alone.
Therefore, the b-conglycinin was able to reverse the
increase in the liver weight and hepatosomatic index of
the animals that ingested rosuvastatin, but not those of the
7S+FF animals.
The protein b-conglycinin has been studied for its
effects on dyslipidemia, both as a single protein added
to the diet, and as a daily dose [7,8,10,12-14,37,38], and
in both cases distinct effects on lipid metabolism were
observed. Studies using animals subjected to a daily
dose of b-conglycinin [13-15], and our study, show that
the 7S protein has an effect comparable to that of rosu-
vastatin, but weaker than fenofibrate, in reducing levels
of total cholesterol. Surprisingly, the b-conglycinin/rosu-
vastatin combination raised the total cholesterol to a
higher level than in any other group, even the hypercho-
lesterolemic group, while the combination with fenofi-
brate led to lower values of TC than either separately.
The LDL-C/HDL-C ratio is used as risk factor for cor-
onary heart diseases (CHD), on account of the effect of
each fraction on the atherosclerotic process [39]. Thus,
the atherogenic index (AI) of the hypercholesterolemic
diet group (HC), in this experiment, was 8 times higher
than that of rats on the casein standard diet [14], as also
observed by other authors [10]. All treatments resulted in
reductions in AI of the animals, the combination of 7S
protein and fenofibrate (HC+7S+FF group) being the
most efficient, followed by fenofibrate (HC+FF group),
protein (HC+7S group), protein plus rosuvastatin (HC
+7S+RO group) and rosuvastatin (HC+RO group), with
falls of 81, 76, 57, 55 and 50%, relative to HC, respectively
(Table 4). These data indicate that the protein-fenofibrate
and protein-rosuvastatin combinations resulted in lower
cardiovascular risks than di dt h ed r u g sa l o n e( T a b l e4 ) .
Even though the combination of protein with rosuvasta-
tin rose the level of total cholesterol approximately to
that observed in the group HC, the combination reduced
the cardiovascular risk by increasing the HDL-C fraction
(Table 4).
The mechanisms of action of these drugs are properly
established, as mentioned above. However, the mechan-
isms of action of soybean proteins on lipid metabolism
are not yet clear, as various studies point to different
actions, such as increasing the amount of LDL-receptors
[7,8,40,41], inhibiting HMG-CoA reductase [42], seques-
tering bile acids [38], activiting b-oxidation related
enzymes [38,43], gene expression [40,43] and others
[11,12,38,41]. However, a lot of evidence suggests that
the effects of soybean proteins could be due to biologi-
cally active peptides produced by digestion of the pro-
teins in the gastrointestinal tract, and that these peptides
would be the main agents affecting cholesterol and tria-
cylglyceride metabolism, since the protein itself cannot
be absorbed intact.
The behaviors of these combinations suggest a possible
synergy between the protein and fenofibrate and an antag-
onistic effect with rosuvastatin, in relation to serum total
cholesterol. Although, in the case of rosuvastatin, the
increase in the HDL-C fraction to a level above that with
the protein or drug alone may be due to a higher rate of
cholesterol catabolism, an important function of this frac-
tion is as a carrier of cholesterol to the liver. Fenofibrate
has been characterized as a drug that causes an increase in
HDL-C levels [44], while the literature indicates only a
slight modification of this fraction by the statins, unrelated
to dose [20]. These observations were confirmed by our
experiment, but b-conglycinin had a positive effect in
combination with rosuvastatin, resulting in a higher
increase than with the drug alone. The non-HDL-C levels
followed the same trend as total cholesterol. The combina-
tions of protein with the drugs did not affect the TG levels,
although the rosuvastatin improved the action of the pro-
tein in the combination and reduced the level compared
to the drug alone.
The liver cholesterol concentration was reduced by all
treatments, relative to HC, the greatest reduction (37%)
being seen in the HC+RO group. Nevertheless, 7S-rosu-
vastatin combination annulled the effect of the drug,
showing the same value as the protein alone and much
higher than with the drug alone. The 7S-fenofibrate com-
bination resulted in a fall in concentration of hepatic tria-
cylglycerides, relative to HC and to the drug alone (which
led to a rise in this level), to the same concentration as HC
+FF. However, the fenofibrate, without or with 7S protein,
maintained the hepatosomatic index above that of the HC
group, due to the appreciable increase in the liver weight
of the animals.
The meta-analysis of studies by Anderson et al. [45]
demonstrated a 12.5% reduction in the levels of LDL-C
for 1.5 to 2 oz of soy protein daily (50 g/d), whereas a
recent meta-analysis reported only 4-6% [46]. More
recently, Jenkins et al. [16] discussed the effect of choles-
terol reduction by soy proteins in light of a review of
Ferreira et al. Lipids in Health and Disease 2012, 11:11
http://www.lipidworld.com/content/11/1/11
Page 6 of 8claims for heart health by the U.S. FDA and a meta-
analysis of studies on the action of soy protein; they con-
cluded that soy remains one of the few food components
that reduce serum cholesterol when added to the diet.
Results in the literature show that soybean protein, when
used as the only protein source in the diet affects these
serum parameters in various ways, depending on the
experimental model, animal, dose and other factors [3].
However, when administered as a daily dose in hypercho-
lesterolemic animals fed a standard casein diet, enriched
by cholesterol and cholic acid, it had the effect of redu-
cing TC, LDL-C and TG levels in a dose-dependent man-
ner [13,14]. It is important to note that in our study the
b-conglycinin was administered by gavage, alone and/or
in combination with the drugs at a concentration equiva-
lent to 2.75-2.90% of the daily total protein intake, and
that the doses were given separately to the animals, with
a difference of 6 hours between drug and the protein.
The fact that the b-conglycinin was isolated may be the
cause of its higher effect on the cholesterol metabolism
relative to the total protein or soybean protein products.
We may note that, despite the use of various experimen-
tal models with different in vitro and in vivo approaches,
the mechanism of action of soy protein on lipid metabo-
lism is still controversial and deserves further study, espe-
cially in relation to its interactions with drugs of similar
effect. At the moment, studies to reveal the mechanism
of action of b-conglycinin, alone and combined with sta-
tins are in progress in our lab.
Conclusion
The 7S soybean protein-fenofibrate combination was
shown to have a positive in reducing the serum total cho-
lesterol levels of hypercholesterolemic animals, as well as
raising the levels of HDL-C, and relative to the protein
and drug alone. This enhancing effect was reflected in a
greater reduction of the cardiovascular risk by up to 81%
relative to HC animals. This combination also had a posi-
tive effect on the levels of hepatic triacylglycerides, with a
reduction of 20.6% relative to the drug alone. The associa-
tion of protein-rosuvastatin produced an unexpected
action on serum total cholesterol, maintaining it at the
level shown by the HC group, which was 25 and 21%
higher than those observed with the protein and drug
alone. However, it also caused an increase in HDL-C of
23%, compared to protein and drug alone. Surprisingly, it
achieved a reduction in the cardiovascular risk of 55%,
relative to group HC.
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